1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,900 | 9,350 | 13:07 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:18 | AgomAb Therapeutics NV: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook | 92 | GlobeNewswire (Europe) | -- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --... ► Artikel lesen | |
| Do | Agomab Therapeutics NV - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 26.03. | Agomab receives U.S. patent for lung fibrosis drug candidate | 3 | Investing.com | ||
| 26.03. | AgomAb Therapeutics N.V.: Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis | 113 | GlobeNewswire (Europe) | Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent... ► Artikel lesen | |
| 11.03. | Agomab Therapeutics NV - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.03. | Morgan Stanley initiates Agomab Therapeutics stock with overweight rating | 5 | Investing.com | ||
| 03.03. | Morgan Stanley stuft Agomab Therapeutics mit "Overweight" ein und sieht 73 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 03.03. | JPMorgan initiates Agomab Therapeutics stock at Overweight | 2 | Investing.com | ||
| 03.03. | JPMorgan startet Coverage für Agomab Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| 09.02. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 09.02. | AgomAb Therapeutics N.V.: Agomab Announces Closing of Initial Public Offering | 436 | GlobeNewswire (Europe) | ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| 06.02. | SpyGlass Pharma surges on public debut; AgomAb falls | 4 | Seeking Alpha | ||
| 06.02. | Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut | 1 | Reuters | ||
| 06.02. | NASDAQ-Debüt: Aktie von Agomab Therapeutics startet unter Ausgabepreis | 1 | Investing.com Deutsch | ||
| 06.02. | Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million | 3 | Renaissance Capital | ||
| 06.02. | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | 1 | FierceBiotech | ||
| 06.02. | Agomab, SpyGlass Pharma bank a combined $350M in biotech IPOs | 1 | BioPharma Dive | ||
| 06.02. | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | 377 | GlobeNewswire (Europe) | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| 03.02. | Agomab Therapeutics NV - 8-A12B, Registration of securities | 1 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 22,480 | 0,00 % | Erasca, Inc. - 8-K, Current Report | ||
| ARCELLX | 115,04 | 0,00 % | Gilead Sciences, Inc. Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 22,260 | 0,00 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| ADMA BIOLOGICS | 11,075 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| QIAGEN | 32,210 | -1,01 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| CG ONCOLOGY | 69,90 | 0,00 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| NUVALENT | 108,07 | 0,00 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| INHIBRX BIOSCIENCES | 119,88 | 0,00 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,870 | 0,00 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| BEAM THERAPEUTICS | 30,160 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,080 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,130 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TARSUS PHARMACEUTICALS | 60,94 | 0,00 % | Mizuho senkt Kursziel für Tarsus Pharmaceuticals wegen Umsatzaussichten auf 100 $ | ||
| DYNE THERAPEUTICS | 18,900 | 0,00 % | Shandong Wit Dyne Health Co.,Ltd. Profit Climbs In Full Year | ||
| EVOTEC | 5,230 | -3,15 % | Nahost-Konflikt belastet Märkte: Food-Lieferketten werden zum Schlüsselthema - MustGrow, K+S, Evotec und BioNTech im Fokus | Der Nahost-Konflikt rückt die globalen Lieferketten erneut in den Fokus und erhöht den Druck auf sensible Versorgungswege. Besonders die Straße von Hormus bleibt dabei ein zentraler geopolitischer Risikofaktor... ► Artikel lesen |
Das Unternehmen AGOMAB THERAPEUTICS NV ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,56 % bei einem Aktienkurs von 8,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.